KBC Group NV, headquartered in Brussels, is a bank-insurance group that offers integrated financial services primarily to retail clients, private banking, and small to medium-sized enterprises. The company provides a wide range of products including demand deposits, savings accounts, home and mortgage loans, consumer finance, and SME funding. Additionally, KBC Group offers various insurance products, investment fund and asset management services, cash management, payments, trade finance, and corporate finance. As of December 31, 2019, KBC operated numerous branches across Belgium, the Czech Republic, Hungary, Bulgaria, and Ireland, serving customers through various channels, including agents and electronic platforms. KBC Private Equity, a division of KBC Group, focuses on providing development capital and financing for buy-outs in Belgium and Central and Eastern Europe, managing a diverse portfolio valued at over EUR 400 million. Founded in 1935 and rebranded in 2005, KBC Group continues to emphasize a long-term commitment to its investments and clients.
Wizata is make sense of your data and discover unique solutions and unexploited opportunities. Wizata proposes vertical solutions answering to your specific sector challenges. As main domains of expertize, Wizata counts today the Manufacturing (Industry 4.0), Insurance, Energy, Healthcare sectors and e-commerce for predictive management and process optimization.
By embedding themselves in your business and synergising with your teams, WIZATA’s data scientists uncover hidden gems within your data, whether internal or external to your organisation.
Every profile is an exception, that’s why WIZATA offers an advanced collaboration model with people who are real experts in data science.
Unique profiles for unique services.
ArtiQ NV develops ArtiQ|PFT, an artificial intelligence-based medical software that helps doctors to diagnose, treat, and monitor respiratory problems. Its software automatically processes pulmonary function test data and generates a clinical report. ArtiQ NV was founded in 2019 and is based in Leuven, Belgium.
Fnality International provides a digital cash system that uses blockchain technology to settle financial transactions. It was established in April 2019 and is headquartered in London, England. Fnality is the commercial realisation of a four-year Research & Development project called the "Utility Settlement Coin," which was first proposed by UBS and London-based blockchain company Clearmatics.
Joyn Belgium operates a customer engagement platform that enhances the relationship between merchants and their customers. The platform allows users to utilize a loyalty card that enables them to earn rewards points while shopping at their preferred stores. Customers can redeem these points for various benefits, including discounts and prizes, fostering loyalty and repeat business. By integrating the efforts of numerous local merchants, Joyn provides a unified app that offers unique advantages to customers, encouraging them to return to participating businesses. This approach not only supports merchants in growing their customer base but also helps consumers discover valuable rewards and promotions from a diverse range of local retailers.
United Bulgarian Bank provides various banking products and services to individual, microbusiness, and corporate clients in Bulgaria. Its deposit products include savings accounts, current accounts, online deposits and accounts, and cash management accounts. The company also offers various loan products, including consumer loans, mortgage loans, overdrafts, revolving credit lines, working capital loans, investment loans, credit lines, agriculture loans, loans under European programs, guarantee programs, and credit programs, as well as debit and credit cards.
UBB Interlease is a Bulgarian lease company part of the Belgian banking and insurance group KBC. The activities of Interlease are targeted towards increasing the competitiveness and improving the market positions of the Bulgarian enterprises both domestically and abroad. Interlease finances the acquisition of high-quality equipment, transportation vehicles, cars and office equipment. The company provides its customers with professional service after delivery of the asset, based on effective internet and mobile technologies.
CitizenLab NV is a civic engagement software company based in Brussels, Belgium, founded in 2015. The company offers a platform designed for city governments to enhance citizen participation in decision-making processes. Its features enable two-way communication between local authorities and residents, allowing citizens to propose and discuss ideas, vote on them, and provide feedback through polls and surveys. The platform also includes tools for city managers to visualize decision-making through timelines and maps, as well as analytics and reporting features to facilitate informed decision-making. By promoting transparency and collaboration, CitizenLab aims to make governance more democratic and effectively engage citizens in shaping their communities.
VB LEASING SK, spol. s r.o., a leasing company, focuses on financing movable objects. It finances personal and utility vehicles, machines, equipment and technologies, and computing technology solutions. It also offers financing through credit. The company serves corporate and private clients in Slovakia. VB LEASING SK, spol. s r.o. was formerly known as LB-Leasing spol. s r.o. and changed its name to VB LEASING SK, spol. s r.o. in 2002. The company was founded in 1994 and is headquartered in Bratislava, Slovakia. As of July 21, 2015, VB LEASING SK, spol. s r.o. operates as a subsidiary of CSOB Leasing, a.s..
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
BIC specialises in assisting international investors in acquiring businesses, as well as local companies in attracting strategic partners, and can look back on a number of successfully completed M&A transactions. From one region to another, the value of the deals it works on varies between 10 and 200 million euros. Its business portfolio is spread evenly across the various regions in which the company operates. BIC targets midcaps and is a strong player in the financial services, consumer goods, retail, distribution and selected industrial sectors.
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Istrobanka is a provider of retail and wholesale banking products and services for corporate and individual customers in Slovakia. The company offers deposit products, savings and investment accounts, loans, corporate finance, insurance products, payment cards, mutual funds, and mortgage loans.
Richelieu Finance
Acquisition in 2008
Richelieu Finance is an investment management company.
Ceres, Inc. is an agricultural biotechnology company based in Thousand Oaks, California, that focuses on developing and marketing seeds and traits for various crop applications, including feed, forages, and renewable biomass. The company employs advanced plant breeding, biotechnology, and bioinformatics to create seed products that improve yields, enhance resilience to drought, and address other agricultural challenges. Ceres specializes in forage sorghum seeds for livestock feeding and offers energy crops like sweet sorghum and high biomass sorghum, which can be utilized for biofuel production and biomass energy generation. The company's products are marketed under the Blade brand. In addition to its seed offerings, Ceres has developed the Persephone bioinformatics software to facilitate the management and visualization of complex genetic data. Founded in 1996, Ceres, Inc. became a subsidiary of Land O’ Lakes Inc. in 2016.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Absolut Bank was established in 1993. The bank has about 200 thousand clients all over Russia. The bank has more than 30 thousand corporate clients from different economic sectors such as consumer goods, metals, machine-building, automobile, oil, energy, food and processing industries, telecommunications and information technologies, construction, commerce, transportation, pharmaceutical industry and medical equipment production, publishing and printing, chemical industry, agribusiness and other branches. Absolut Bank offers all of its corporate clients a full spectrum of financial services, including all types of financing, a package of cash and settlement services, additional investment and other opportunities. One of the strategic priorities for Absolut Bank is development of services in the segment of individual clients. In every area of its business, the bank offers new terms, some of them being the most attractive in the market, and excellent service.
Romstal Leasing is the largest independent leasing company in Romania. At the end of 2006, it held a 4.20% share of the Romanian leasing market and was ranked thirteenth. The bulk of its financing activity (43.30%) relates to car leasing, but it also leases delivery vans, lorries, machinery and equipment and real estate.
Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.
Banco Urquijo specializes in advising and managing legal entities, such as insurance companies, mutual companies, provident societies, cooperatives, and trusts that administer third party assets.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
K&H Bank is a banking institution based in Budapest, Hungary, established in 1987. It operates in both retail and corporate segments, offering a wide range of financial services and solutions. These services include corporate finance, agricultural loans, leasing, and funding for local governments. As a wholly owned subsidiary of KBC Bank, K&H Bank focuses on providing its clients with comprehensive financial advice to help them make informed decisions.
HSBC Dewaay SA is a privately held company offers private banking and trustee services. It services include cash management, discretionary portfolio management, and patrimonial advisory services.
Effectenbank Stroeve N.V.
Acquisition in 2005
Effectenbank Stroeve N.V. is a privately held company offers capital management, stockbroking, and investment advisory services.
Aurel Leven
Acquisition in 2005
Aurel Leven Gestion, an independent asset management company, old, which manages funds on behalf of private clients and institutional investors. Aurel Leven Gestion, of February 2005, Aurel Leven Gestion was acquired by KBL France Gestion.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
WARTA S.A. was established in 1920. Since then it's been setting standards on the Polish insurance market. The Company is one of the largest and oldest insurance companies in Poland.